Abpro to present first preclinical data for bispecific HER2 x CD3 T-cell engager at AACR 2025

Abpro Holdings, Inc.

Oral presentation of ABP-102/CT-P72 at AACR 2025 in New Drugs on the Horizon session on April 27, 2025.
ABP-102/CT-P72 is a tetravalent bispecific HER2 x CD3 T-cell engager developed under a strategic partnership with Celltrion.
Data are under embargo until presentation; no results disclosed.
Presenter: Adam J. Pelzek, Ph.D., Associate Director at Abpro.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.